Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The effects of the combined use of a PDE5 inhibitor and medications for hypertension, lower urinary tract symptoms and dyslipidemia on corporal tissue tone

International Journal of Impotence Research volume 24, pages 221–227 (2012)Cite this article

Subjects

Abstract

ED is closely associated with its comorbidities (hypertension, dyslipidemia and lower urinary tract symptoms (LUTS)). Therefore, several drugs have been prescribed simultaneously with PDE5 inhibitors. If a specific medication for ED comorbidities has enhancing effects on PDE5 inhibitors, it offers alternative combination therapy in nonresponders to monotherapy with PDE5 inhibitors and allows clinicians to treat ED and its comorbidities simultaneously. To establish theoretical basis of choosing an appropriate medication for ED and concomitant disease, we examined the effects combining a PDE5 inhibitor with representative drugs for hypertension, dyslipidemia and LUTS on relaxing the corpus cavernosum of rabbits using the organ-bath technique. The effect of mirodenafil on relaxing phenylephrine-induced cavernosal contractions was significantly enhanced by the presence of 10−4 M losartan, 10−6 M nifedipine, 10−6 M amlodipine, 10−7 M doxazosin and 10−9 M tamsulosin (P<0.05). The maximum relaxation effects were 47.2±3.8%, 57.6±2.6%, 64.0±3.7%, 76.1±5.7% and 71.7±5.4%, respectively. Enalapril and simvastatin had no enhancing effects. The relaxation induced by sodium nitroprusside alone (39.0±4.0%) was significantly enhanced in the presence of the 10−4 M losartan (66.0±6.0%, P<0.05). Tetraethylammonium (1 mM) significantly inhibited the enhancement effects of tamsulosin and doxazosin on mirodenafil-induced relaxation (doxazosin: 76.1±5.7% vs 45.3±2.3%; tamsulosin: 71.7±5.4% vs 48.1±3.5%). On the basis of these findings, losartan seemed to induce synergistic effects through an interaction with nitric oxide. In addition, K+ channel activation could be one of the mechanisms for the synergistic effect of combining mirodenafil with doxazosin or tamsulosin. We believe that the combination of a PDE5 inhibitor with losartan, nifedipine, amlodipine, doxazosin or tamsulosin could be a pharmacologic strategy for simultaneously treating ED and its comorbidities and increasing response rates to PDE5 inhibitors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  PubMed  Google Scholar 

  2. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.

    Article  PubMed  Google Scholar 

  3. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

    Article  Google Scholar 

  4. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS . Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004; 64: 1196–1201.

    Article  PubMed  Google Scholar 

  5. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188–1191.

    Article  CAS  PubMed  Google Scholar 

  6. Walczak MK, Lokhandwala N, Hodge MB, Guay AT . Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5: 19–24.

    PubMed  Google Scholar 

  7. Muller SC, el-Damanhoury H, Ruth J, Lue TF . Hypertension and impotence. Eur Urol 1991; 19: 29–34.

    Article  CAS  PubMed  Google Scholar 

  8. Ponholzer A, Temml C, Rauchenwald M, Madersbacher S . Vascular risk factors and erectile dysfunction in a cohort of healthy men. Int J Impot Res 2006; 18: 489–493.

    Article  CAS  PubMed  Google Scholar 

  9. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.

    Article  CAS  PubMed  Google Scholar 

  10. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R . Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–574; discussion 574-565.

    Article  CAS  PubMed  Google Scholar 

  11. Blanker MH, Bosch JL, Groeneveld FP, Bohnen AM, Prins A, Thomas S et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57: 763–768.

    Article  CAS  PubMed  Google Scholar 

  12. Nicolosi A, Glasser DB, Moreira ED, Villa M . Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003; 15: 253–257.

    Article  CAS  PubMed  Google Scholar 

  13. Hansen BL . Lower urinary tract symptoms (LUTS) and sexual function in both sexes. Eur Urol 2004; 46: 229–234.

    Article  PubMed  Google Scholar 

  14. Lau DH, Thompson CS, Bellringer JF, Thomas PJ, Mumtaz FH, Morgan RJ et al. Doxazosin and serotonin (5-HT) receptor (1A, 2A, and 4) antagonists inhibit 5-HT-mediated human cavernosal contraction. J Androl 2006; 27: 679–685.

    Article  CAS  PubMed  Google Scholar 

  15. Palea S, Barras M . Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int 2003; 91: 873–877.

    Article  CAS  PubMed  Google Scholar 

  16. Kerfoot WW, Park HY, Schwartz LB, Hagen PO, Carson III CC . Characterization of calcium channel blocker induced smooth muscle relaxation using a model of isolated corpus cavernosum. J Urol 1993; 150: 249–252.

    Article  CAS  PubMed  Google Scholar 

  17. Ma LL, Liu YQ, Tang WH, Zhao LM, Jiang H . Experimental study of verapamil on the relaxation of isolated human corpus cavernosum tissues. Asian J Androl 2006; 8: 195–198.

    Article  CAS  PubMed  Google Scholar 

  18. Ushiyama M, Kuramochi T, Katayama S . Treatment with hypotensive agents affects the impaired relaxation of the penile corpus cavernosum in hypertensive rats. Hypertens Res 2006; 29: 523–532.

    Article  CAS  PubMed  Google Scholar 

  19. Dusing R . Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65: 773–786.

    Article  PubMed  Google Scholar 

  20. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, Argaya Roca M, Pol Bravo C, Sanchez Zamorano MA et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–341.

    Article  CAS  PubMed  Google Scholar 

  21. Dusing R . Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29–34.

    Article  CAS  PubMed  Google Scholar 

  22. Baumhakel M, Custodis F, Schlimmer N, Laufs U, Bohm M . Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J Pharmacol Exp Ther 2008; 327: 692–698.

    Article  PubMed  Google Scholar 

  23. Bell AS, Palmer MJ . Novel phosphodiesterase type 5 modulators: a patent survey (2008–2010). Expert Opin Ther Pat 2011; 21: 1631–1641.

    Article  CAS  PubMed  Google Scholar 

  24. Renwick AG, Robertson DR, Macklin B, Challenor V, Waller DG, George CF . The pharmacokinetics of oral nifedipine—a population study. Br J Clin Pharmacol 1988; 25: 701–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Liu Y, Jia J, Liu G, Li S, Lu C, Yu C . Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Clin Ther 2009; 31: 777–783.

    Article  CAS  PubMed  Google Scholar 

  26. Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther 2009; 31: 3009–3020.

    Article  CAS  PubMed  Google Scholar 

  27. Farthing D, Sica D, Fakhry I, Pedro A, Gehr TW . Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. J Chromatogr B Biomed Sci Appl 1997; 704: 374–378.

    Article  CAS  PubMed  Google Scholar 

  28. Prasaja B, Harahap Y, Lusthom W, Setiawan EC, Ginting MB, Hardiyanti et al. A bioequivalence study of two tamsulosin sustained-release tablets in Indonesian healthy volunteers. Eur J Drug Metab Pharmacokinet 2011; 36: 109–113.

    Article  CAS  PubMed  Google Scholar 

  29. Sripalakit P, Nermhom P, Maphanta S, Polnok S, Jianmongkol P, Saraphanchotiwitthaya A . Bioequivalence evaluation of two formulations of doxazosin tablet in healthy thai male volunteers. Drug Dev Ind Pharm 2005; 31: 1035–1040.

    Article  CAS  PubMed  Google Scholar 

  30. Song JC, White CM . Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41: 207–224.

    Article  CAS  PubMed  Google Scholar 

  31. Najib NM, Idkaidek N, Adel A, Admour I, Astigarraga RE, Nucci GD et al. Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm Drug Dispos 2003; 24: 183–189.

    Article  CAS  PubMed  Google Scholar 

  32. Silva LF, Nascimento NR, Fonteles MC, de Nucci G, Moraes ME, Vasconcelos PR et al. Phentolamine relaxes human corpus cavernosum by a nonadrenergic mechanism activating ATP-sensitive K+ channel. Int J Impot Res 2005; 17: 27–32.

    Article  CAS  PubMed  Google Scholar 

  33. El-Metwally MA, Sharabi FM, Daabees TT, Senbel AM, Mostafa T . Involvement of alpha-receptors and potassium channels in the mechanism of action of sildenafil citrate. Int J Impot Res 2007; 19: 551–557.

    Article  CAS  PubMed  Google Scholar 

  34. Kim NN, Goldstein I, Moreland RB, Traish AM . Alpha-adrenergic receptor blockade by phentolamine increases the efficacy of vasodilators in penile corpus cavenosum. Int J Impot Res 2000; 12 (Suppl 1): S26–S36.

    Article  PubMed  Google Scholar 

  35. Angulo J, Cuevas P, Fernandez A, Gabancho S, Saenz de Tejada I . Combination of phentolamine and L-arginine or sildenafil synergistically improves neurogenic relaxation of rabbit corpus cavernosum smooth muscle. Urology 2001; 57: 585–589.

    Article  CAS  PubMed  Google Scholar 

  36. Porst H . The future of erectile dysfunction (ED). Arch Esp Urol 2010; 63: 740–747.

    PubMed  Google Scholar 

  37. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST . Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300: 2867–2878.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Iwamoto Y, Song K, Takai S, Yamada M, Jin D, Sakaguchi M et al. Multiple pathways of angiotensin I conversion and their functional role in the canine penile corpus cavernosum. J Pharmacol Exp Ther 2001; 298: 43–48.

    CAS  PubMed  Google Scholar 

  39. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U et al. Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology 2001; 58: 805–810.

    Article  CAS  PubMed  Google Scholar 

  40. Ertemi H, Mumtaz FH, Howie AJ, Mikhailidis DP, Thompson CS . Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: modulation of nitric oxide mediated relaxation. J Urol 2011; 185: 2414–2420.

    Article  CAS  PubMed  Google Scholar 

  41. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG . Tissue angiotensin II as a modulator of erectile function I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920–1925.

    Article  CAS  PubMed  Google Scholar 

  42. Nakamaru M, Jackson EK, Inagami T . Role of vascular angiotensin II released by beta-adrenergic stimulation in rats. J Cardiovasc Pharmacol 1986; 8 (Suppl 10): S1–S5.

    Article  CAS  PubMed  Google Scholar 

  43. Kifor I, Dzau VJ . Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ Res 1987; 60: 422–428.

    Article  CAS  PubMed  Google Scholar 

  44. Sadoshima J, Xu Y, Slayter HS, Izumo S . Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977–984.

    Article  CAS  PubMed  Google Scholar 

  45. Touyz RM, Schiffrin EL . Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001; 19: 1245–1254.

    Article  CAS  PubMed  Google Scholar 

  46. Cai H, Harrison DG . Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840–844.

    Article  CAS  PubMed  Google Scholar 

  47. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 1044–1048.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Sarikaya S, Asci R, Aybek Z, Yilmaz AF, Buyukalpelli R, Yildiz S . Effects of intracavernous calcium channel blockers in dogs. Int Urol Nephrol 1997; 29: 673–680.

    Article  CAS  PubMed  Google Scholar 

  49. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ . Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 1994; 74: 365–507.

    Article  CAS  PubMed  Google Scholar 

  50. Lau LC, Adaikan PG . Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. Eur J Pharmacol 2006; 541: 184–190.

    Article  CAS  PubMed  Google Scholar 

  51. Kaplan SA, Gonzalez RR, Te AE . Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717–1723.

    Article  CAS  PubMed  Google Scholar 

  52. De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G . Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002; 14: 50–53.

    Article  CAS  PubMed  Google Scholar 

  53. El-Gamal OM, Sandhu DP, Terry T, Elliott RA . alpha-Adrenoceptor subtypes in isolated corporal tissue from patients undergoing gender re-assignment. BJU Int 2006; 97: 329–332.

    Article  CAS  PubMed  Google Scholar 

  54. Furukawa K, Chess-Williams R, Uchiyama T . Alpha 1B-adrenoceptor subtype mediating the phenylephrine-induced contractile response in rabbit corpus cavernosum penis. Jpn J Pharmacol 1996; 71: 325–331.

    Article  CAS  PubMed  Google Scholar 

  55. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D . Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996; 16: 21–28.

    Article  CAS  PubMed  Google Scholar 

  56. Praveen R . Tamsulosin – turn a round: a review. Int J Current Biol Med Sci 2011; 1: 39–40.

    Google Scholar 

  57. Rattan S . 3-Hydroxymethyl coenzyme A reductase inhibition attenuates spontaneous smooth muscle tone via RhoA/ROCK pathway regulated by RhoA prenylation. Am J Physiol Gastrointest Liver Physiol 2010; 298: G962–G969.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Shultz PJ, Raij L . Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations. Br J Clin Pharmacol 1989; 28 (Suppl 2): 151S–157S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Korean Health Technology R & D Project, Ministry for Health &Welfare, Republic of Korea (A090583).

Author information

Authors and Affiliations

  1. Genitourinary Disease Oriented Translational Research, Seoul, Korea

    J H Lee, M R Chae, J K Park, J H Jeon & S W Lee

  2. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    J H Lee, M R Chae & S W Lee

  3. Department of Urology, Jeonbuk National University of Medicine, Jeonju, Korea

    J K Park

  4. Department of Physiology, Seoul National University School of Medicine, Seoul, Korea

    J H Jeon

Authors
  1. J H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M R Chae
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J K Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J H Jeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S W Lee.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, J., Chae, M., Park, J. et al. The effects of the combined use of a PDE5 inhibitor and medications for hypertension, lower urinary tract symptoms and dyslipidemia on corporal tissue tone. Int J Impot Res 24, 221–227 (2012). https://doi.org/10.1038/ijir.2012.19

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2012.19

Keywords

Search

Advanced search

Quick links